Navigation Links
Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
Date:5/10/2010

el modulation and orphan G protein-coupled receptor identification and established a transcriptional profiling lab to apply leading gene expression technologies to exploratory research efforts.  Dr. Novak performed his post-doctoral training at Yale University School of Medicine in immunobiology, received his Ph.D. in biology from California Institute of Technology, and graduated magna cum laude from Amherst College in Massachusetts with a B.A. in biology and chemistry.  He is the author of more than 45 scientific abstracts and publications.

"Fate Therapeutics is the first company to singularly pursue adult stem cells as therapeutic targets of conventional drug discovery," said Dr. Novak. "I look forward to working with the unmatched team at Fate to translate the Company's unique approach to novel stem cell biology for the discovery and development of a pipeline of new medicines for a broad range of diseases and conditions."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes.  The Company's award-winning, proprietary iPSC technology platform incorporates the most advanced viral, small molecule and protein reprogramming methods and offers a highly efficient, minimally invasive system to recapitulate human physiology for commercial scale drug discovery and therapeutic use.  The Company's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.  Fate Therapeutics is currently conducting a Phase
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
2. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
3. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
4. Silence Therapeutics Appoints New Vice President of Research
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
7. invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial
8. Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
9. Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients
10. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
11. Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MITs Technology Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , , , ATLANTA, ... Elite cardiovascular surgeons from around the world will travel to suburban Atlanta this ... discuss current peer-reviewed data relating to the survival advantage of the Ross Procedure ... , , , , The Ross Procedure ...
... , ST. PAUL, Minn., Sept. 21 ... of its XenMatrix(R) device to Davol Inc., a subsidiary of C.R. ... and related assets of the hernia products business of Brennen Medical, ... device for use in soft tissue repair including hernia and abdominal ...
... CLEVELAND, Ohio, September 21 ... systems, just released,two new products: a new Laparoscopic Essential ... for patient-specific simulation,based on actual patient data - the ... new Laparoscopic Essential Tasks Module is an addition to ...
Cached Biology Technology:Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 2Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 4Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 5Brennen Medical Announces Sale of XenMatrix(R) 2Simbionix USA Corporation's Innovative Development Division Releases Two New Breakthrough Technologies 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... a suspect gene may increase susceptibility to anxiety and ... People with the depression-linked gene variant showed less gray ... well the circuit was connected accounted for nearly 30 ... Institute of Health's (NIH) National Institute of Mental Health ...
... heart attack have long been treated with morphine to ... Duke Clinical Research Institute has shown that these patients ... , The researchers call for a randomized clinical trial ... begin treatment with sufficient doses of nitroglycerin to relieve ...
... by fruit fly geneticists for more than a decade ... in mice. , Writing in the May 6 edition ... a streamlined method for creating a "genetic mosaic mouse"--a ... clusters of cells with mutated genes. , The new ...
Cached Biology News:Depression gene may weaken mood-regulating circuit 2Depression gene may weaken mood-regulating circuit 3Morphine for Chest Pain Increases Death Risk 2Morphine for Chest Pain Increases Death Risk 3Mosaic mouse technique offers a powerful new tool to study diseases and genetics 2Mosaic mouse technique offers a powerful new tool to study diseases and genetics 3
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: